Everything below concerns HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-02. Numbers and descriptions here follow the published literature rather than marketing material.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
| Property | Value | Notes |
|---|---|---|
| Receptor target | Growth hormone-releasing hormone receptor | G-protein-coupled receptor expressed on pituitary somatotroph cells |
| Primary signaling route | Cyclic AMP and protein kinase A | Increases intracellular calcium and promotes hormone release |
| Downstream marker | Insulin-like growth factor 1 | Blood concentration used as an integrated activity indicator |
| Study endpoint | Change in visceral adipose tissue | Assessed with computed tomography in trial populations |
| Research status | Investigational outside the approved indication | Trials in cognitive impairment did not meet primary endpoints |
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from truncated or oxidized forms. Mass spectrometry confirms the expected molecular weight, and peptide mapping after enzymatic digestion verifies the amino acid sequence. Water content is measured because residual moisture affects stability, and tests for aggregates or particulates are standard for injectable peptides. Circular dichroism can indicate whether the molecule has adopted an unexpected secondary structure in solution.
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
Jacobson JB; Kaplan NO (1957). "A reduced pyridine nucleotide pyrophosphatase". J. Biol. Chem. 226 (1): 427–437. doi:10.1016/S0021-9258(18)64843-4. PMID 13428775. Kornberg A; Pricer WE (1950). "Nucleotide pyrophosphatase". J. Biol. Chem. 182 (2): 763–778. doi:10.1016/S0021-9258(18)56512-1. Kumar SA, Rao NA, Vaidyanathan CS (1965). "Nucleotidases in plants. I. Partial purification and properties of the enzyme hydrolyzing flavine adenine dinucleotide from mung bean seedlings (Phaseolus radiatus)". Arch. Biochem. Biophys. 111 (3): 646–52. doi:10.1016/0003-9861(65)90246-8. PMID 5862212. Swartz MN, Kaplan NO, Lamborg MF (1958). "A "heat-activated" diphosphopyridine nucleotide pyrophosphatase from Proteus vulgaris". J. Biol. Chem. 232 (2): 1051–1063. doi:10.1016/S0021-9258(19)77421-3. PMID 13549486.
transgene Any gene or other segment of genetic material that has been isolated from one organism and then transferred either naturally or by any of a variety of genetic engineering techniques into another organism, especially one of a different species. Transgenes are usually introduced into the second organism's germ line. They are commonly used to study gene function or to confer an advantage not otherwise available in the unaltered organism.
=== Physicochemical factors affecting carbon nanotube toxicity === Numerous studies have identified key physicochemical properties of carbon nanotubes (CNTs) that influence their biological interactions and toxicological profiles in both in vitro and in vivo systems: Aspect ratio, length, and rigidity: Long and rigid CNTs exhibit increased biopersistence and are strongly associated with fibrogenesis, through the activation of the Smad2/3 and ERK1/2 signaling pathways. Their high aspect ratio and fiber-like morphology, reminiscent of asbestos, can impair macrophage-mediated clearance, and induce inflammation, fibrotic tissue remodeling, granuloma formation, and even DNA damage. Multi-walled carbon nanotubes (MWCNTs) with lengths ranging from approximately 0.5 to 10 μm have been implicated in severe pulmonary conditions, including asbestosis-like fibrosis and mesothelioma. Similarly, single-walled carbon nanotubes (SWCNTs) exceeding 10 μm in length can induce granulomatous lesions. In contrast, shorter SWCNTs—particularly those under 300 nm and well-dispersed—are more readily cleared from the body via renal and biliary excretion pathways. These shorter, purified SWCNTs have demonstrated significantly reduced inflammatory and cytotoxic responses and, to date, lack conclusive evidence of carcinogenicity. Aggregation state: The aggregation state of CNTs refers to their propensity to cluster into bundles or agglomerates, primarily driven by van der Waals forces and electrostatic interactions.
Sources: en.wikipedia.org
As a consequence of widespread and injudicious use of antibacterials, there has been an accelerated emergence of antibiotic-resistant pathogens, resulting in a serious threat to global public health. The resistance problem demands that a renewed effort be made to seek antibacterial agents effective against pathogenic bacteria resistant to current antibacterials. Possible strategies towards this objective include increased sampling from diverse environments and application of metagenomics to identify bioactive compounds produced by currently unknown and uncultured microorganisms as well as the development of small-molecule libraries customized for bacterial targets.
On June 22, 1941, Germany broke the Molotov–Ribbentrop Pact with Operation Barbarossa, the invasion of the Soviet Union through the territories that the two countries had previously divided. Stalin switched his cooperation from Hitler to Winston Churchill. Britain and the Soviets signed a formal alliance, but the US did not join until after the Attack on Pearl Harbor on December 7, 1941. Immediately, there was disagreement between Britain's ally Poland and the Soviet Union. The British and Poles strongly suspected that when Stalin was cooperating with Hitler, he ordered the execution of about 22,000 Polish officer POWs, at what was later to become known as the Katyn massacre. Still, the Soviets and the Western Allies were forced to cooperate, despite their tensions. The US shipped vast quantities of Lend-Lease material to the Soviets. Britain agreed a broader military and political alliance in 1942. During the war, both sides disagreed on military strategy, especially the question of the opening of a second front against Germany in Western Europe. As early as July 1941, Stalin asked Britain to invade northern France, but Britain was in no position to carry out such a request. Stalin had also requested that the Western Allies open a second front from the early months of the war—which finally occurred on D-Day, June 6, 1944. The US and Britain initially indicated that they would open the second front in 1942, and then in 1943, but it was postponed both times.
==== 2.B Nonribosomally synthesized porters ==== 2.B.1 The Valinomycin Carrier Family 2.B.2 The Monensin Family 2.B.3 The Nigericin Family 2.B.4 The Macrotetrolide Antibiotic (MA) Family 2.B.5 The Macrocyclic Polyether (MP) Family 2.B.6 The Ionomycin Family 2.B.7 The Transmembrane α-helical Peptide Phospholipid Translocation (TMP-PLT) Family 2.B.8 The Bafilomycin A1 (Bafilomycin) Family 2.B.9 The Cell Penetrating Peptide (CPP) Functional Family 2.B.10 The Synthetic CPP, Transportan Family 2.B.11 The Calcimycin or A23187 Carrier-type Ionophore Family 2.B.12 The Salinomycin Family 2.B.13 The Tetrapyrrolic Macrocyclic Anion Antiporter (TPMC-AA) Family 2.B.14 The Lasalocid A or X-537A Ionophore (Lasalocid) Family 2.B.15 The Tris-thiourea Tripodal-based Chloride Carrier (TTT-CC) Family 2.B.16 The Halogen-bond-containing Compound Anion Carrier (HCAC) Family 2.B.17 The Isophthalaminde Derivative H+:Cl− Co-transporter (IDC) Family 2.B.18 The Pyridine-2,6-Dicarboxamine Derivative (PDCA) H+:Cl− Co-transporter Family 2.B.19 The Calix(4)pyrrole Derivative (C4P) Family 2.B.20 The Prodigiosin (Prodigiosin) Chloride/Bicarbonate Exchanger Family 2.B.21 The ortho-Phenylenediamine-bis-Urea Derivative Anion Transporter (oPDA-U) Family 2.B.22 The Imidazolium-functionalized Anion Transporter (IAT) Family 2.B.23 The Homotetrameric Transmembrane Zn2+/Co2+:Proton Synthetic Antiporter, Rocker (Rocker) Family 2.B.24 The 2,6-Bis(benzimidazol-2-yl)pyridine Anion Carrier (BBP-AC) Family 2.B.25 The Peptide-mediated Lipid Flip-Flop (PLFF) Family 2.B.26 The Bis(imidazolyl)-functionalized Bis(Choloyl) Conjugate (BIBCC) Family 2.B.27 The Tris-Urea Anion Transporter Family 2.B.29 The Anionophoric Marine Alkaloid Tambjamine Family
=== Androgen deficiency === Primary hypogonadism (indicating an intrinsic problem with the testes in males) leads to decreased testosterone synthesis and increased conversion of testosterone to estradiol, potentially leading to a gynecomastic appearance. Klinefelter syndrome is a notable example of a disorder that causes hypogonadism and gynecomastia, and has a higher risk of breast cancer in males (20–50 times higher than males without the disorder). Secondary hypogonadism (indicating a problem with the brain) leads to decreased production and release of luteinizing hormone (LH, a stimulatory signal for endogenous steroid hormone synthesis) which leads to decreased production of testosterone and estradiol in the testes.
Sources: en.wikipedia.org
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.
Insulin-like growth factor 1 is a downstream product of growth hormone action and changes more slowly than the hormone itself. Its blood concentration is used as an integrated indicator of whether the pathway has been stimulated. Interpretation requires attention to nutrition, illness, and other factors that shift IGF-1 independently.
No. The approved indication concerns excess visceral abdominal fat in adults with HIV infection and lipodystrophy, a specific clinical population. It is not cleared for general weight reduction or for cosmetic use. Studies in other groups remain investigational.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.